Selvsagt omsettes ikke Oncoinvent til 70 kroner aksjen!
Selskapet er ikke i gang med kliniske studier enda, har 9-12 år frem til markedet, og har bare et produkt under utvikling som ikke er på langt nær så avansert som feks Nano sitt Betalutin.
Prisen til 38 kroner aksjen som ble satt i emisjonen i 2017 var et resultatet av hypen rundt Nano. Forutsetningen da var at man skulle søke om godkjenning som medical device i 2020. Dere må gjerne drømme dere tilbake til den gang, men å snakker om kurser over 38 kroner er utopi og drømmeri.

Til orientering: Merlin og Bateman snakker tull mot bedre vitende. Museforsøkene er så bra at man må ta livet av musene før de dør av alderdom.

I Nano sine museforsøk ja. I Oncoinvent sine forsøk er alle død etter 40-50 dager, mot 20 dager for musene som fikk NaCL.

Dette står i presentasjonen fra januar 2017.

Ting har skjedd siden... :)

Å,? De viser til samme tall i siste publisering også

https://www.transonc.com/article/S1936-5233(17)30417-5/fulltext

http://www.oncoinvent.com
.

Bateman:
Ikke bli nervøs. Jeg har kontroll. :)

Ble du rolig nå?

Og det er evigheter siden Aksjeinvest. Får du solgt den til emisjonskurs i dag bør du være strålende fornøyd.

Heisan!

Da har jeg fått mine første aksjer i onco :)

Pålydende 65 kr pr stykk!

Ha ellers en fin børsdag alle sammen og samt en god helg!

Farvel!

Da har vi omsider fått klarhet i sist omsatte, takk til Nano Rekyl. Kurs 65 er vel omtrent der vi antok.

Oncoinvent har også presentert på EANM, se pressemelding på hjemmesiden www.oncoinvent.com

Limer inn abstractet under:

EP-0788
Alpha-Emitting Radiopharmaceutical for IP Therapy of
Peritoneal Metastases: In Vitro Evaluation and Therapeutic
Effects in a Murine Model
T. B. Bønsdorff1, E. Napoli1,2,3, I. S. Jorstad1, S. Westrøm1,2,3, Ø.
S. Bruland3,2,1, R. H. Larsen4; 1Oncoinvent AS, Oslo, NORWAY,
2University of Oslo, Oslo, NORWAY, 3The Norwegian Radium
Hospital, Oslo University Hospital, Oslo, NORWAY, 4Sciencons AS,
Oslo, NORWAY.
Purpose: Radium-224 (224Ra) labeled calcium carbonate
(CaCO3) microparticles have been developed with the intent
to treat micrometastases located in the abdominal cavity. The
microparticles act as carriers for the α-emitter 224Ra and ensure
high intraperitoneal (IP) retention of the radioactivity without
cellular targeting. This novel α- therapy has a short action range
in tissue and is designed to confine the radiation exposure to
the IP cavity, treating both linings of the peritoneal surfaces as
well as liquid volumes. The retention of radioactivity adsorbed
on the surface of CaCO3 microparticles was examined in vitro
and in vivo. Therapeutic efficacy of the 224Ra-microparticles was
evaluated in a murine xenograft of an ascites presenting human
cell line. Materials and Methods: The retention of 224Ra and its
daughter 212Pb adsorbed on different amounts of CaCO3 microparticles
was evaluated over time both in vitro and in vivo.
Immunodeficient athymic nude mice were used for the in vivo
studies. For investigation of therapeutic effect, mice inoculated
IP with human ovarian cancer cells ES-2 were used. The ES-2 cell
line causes aggressive development of ascites. Varying amounts
of 224Ra-microparticles were administered IP (5-25 mg) with 10-
25 kBq total activity per mice. The treatment was injected the
day after cell inoculation. Survival was assessed. Results: The
retention of 224Ra and its daughter 212Pb on CaCO3 microparticles
increased with increasing amounts of microparticles. This was
observed both in vitro and in biodistribution studies in mice. The
survival studies showed that free cationic 224Ra (given as 224RaCl2
solution) had a therapeutic index (ratio of median survival of
treated mice versus control) of 1.8, whereas administration of
224Ra-labeled CaCO3 microparticles gave a therapeutic index (TI)
up to 2.8. No strong correlation between microparticle amount
and effect on survival in mice with IP xenografts were observed,
at the microparticle amounts tested. The highest amount (25
mg per mice) however, showed inferior survival (TI of 1.7). Conclusion:
Efficient 224Ra-labeling of CaCO3 microparticles was
achieved, with high retention of the radionuclide on the particles
both in vitro and in vivo. Therapeutic studies showed superior
survival when treating with IP injection of 224Ra-CaCO3 microparticle
suspension compared to IP injection of free cationic
224Ra solution. The data also indicate that high concentrations
of particles may potentially reduce the antitumor activity of the
224Ra-CaCO3-suspensions.

http://www.oncoinvent.com/news/495/Oncoinvent-to-present-and-attend-the-32nd-Annual-Congress-of-the-European-Association-of-Nuclear-Medicine

Q3-rapporten ute:

http://www.oncoinvent.com/files/Quarterly-Report-Q3-2018.pdf

Selges nå kjempebillig på 27 kr. sist. Får neppe til den kursen lenger. Oncoinvent er nå i en meget lovende fase og har så langt vist imponerende resultater. Likevel er kursen på et lavmål! Ny CEO i dag.

Oncoinvent appoints Anders Månsson as CEO
Oncoinvent AS, a clinical stage company advancing alpha emitter therapy to treat cancers, today announced the appointment of Anders Månsson as Chief Executive Officer (CEO), effective September 1st, 2023.

"Following a comprehensive search process, it was determined that Anders was the preferred candidate to lead Oncoinvent forward. Anders’s extensive leadership experience in various positions within the pharmaceutical industry, including large multinationals, start-ups, and companies listed on the stock exchange, will add immeasurable value to Oncoinvent, as we advance towards providing best in class therapies to patients in serious need," said Roy Larsen, Ph.D., Chairman of Oncoinvent’s Board of Directors. "On behalf of the Board and everyone at Oncoinvent, I would like to thank Jan Alfheim for his leadership and contributions to our company. We appreciate his commitment to ensuring a seamless transition and we wish him all the best."

"I am honored to join Oncoinvent at this pivotal time in the company’s development, specifically with the continued very promising advancement of Radspherin®. I look forward to collaborating with the Oncoinvent board and management team to develop novel and unique radiopharmaceutical treatments for peritoneal carcinomatosis originating from colorectal and ovarian cancers," said Anders Månsson, newly appointed Chief Executive Officer of Oncoinvent.

Anders has nearly three decades of extensive experience in strategic leadership, business development, and commercialization in the pharmaceutical industry. He has most recently served as CEO of LIDDS, a technology platform company specialising in depot formulations for intra-tumoral injections with its NanoZolid technology. Prior to LIDDS, Anders served as CEO of RhoVac (now CHOSA Oncology AB), a biopharmaceutical company developing immuno-therapeutic treatments for metastatic cancers. Before this, he was CEO and served on the board of directors at Amniotics AB, a clinical stage biotechnology company developing therapies based on stem cells.

Anders has also held several senior management roles in business development in multinational companies such as LEO Pharma and Ferring Pharmaceuticals, spanning close to two decades. Anders currently serves on the board of directors for EQL Pharma AB and Immetric AB, and he has previously held several other board director and advisor positions. Anders holds an M.B.A. from Business School Lausanne and a bachelor’s degree in Business and Economics from Lund University.

There were an estimated 4.8 million new cases of gastrointestinal (GI) cancers and 3.4 million related deaths, worldwide, in 2018. GI cancers account for 26% of the global cancer incidence and 35% of all cancer-related deaths. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630546/

Recommended dose of 7 MBq established following completion of dose escalation; no dose-limiting toxicity observed
Oncoinvent har strålende resultater, på en behandling som til nå ikke foreligger. Med Radspherin forhindres spredningskreft i bukhulen. Dette blir en behandling som vil kunne forhindre flere millioner dødsfall i året.

Selskapsverdien er ekstremt undervurdert.


Jfr: 28 September 2023
Oncoinvent To Present Initial Safety Data from the Phase 1 Trial of Radspherin® in Ovarian Cancer Patients at the 24th Congress of the European Society of Gynaecological Oncology (ESGO)

Oncoinvent in emerging hot spot in oncology
MON, OCT 02, 2023 08:58 CETReport this content
Anders Månsson recently visited BioStock Studio to talk about his new role as CEO of Oncoinvent, a privately held company headquartered in Oslo. The company’s lead candidate is Radspherin, an alpha-radiating radiopharmaceutical developed for the treatment of peritoneal carcinomatosis from colorectal cancer and ovarian cancer. During the interview, Månsson described Radspherin’s mechanism of action and the company’s clinical development plans for the candidate. Furthermore, he shed light on radiopharmaceuticals as an emerging hot spot in oncology attracting great interest from both big pharma and institutional investors.

Watch the interview at biostock.se:

https://www.biostock.se/en/2023/10/oncoinvent-in-emerging-hot-spot-in-oncology/

Meget imponerende presentasjon av Anders Månsson! Han opplyste at de regner med å starte fase IIB forsøk i 1H24 både i Europa og USA. Radspherin viser både efficacy og safety og har ikke vist bivirkninger. Dette bør virkelig bli en biotech-vinner de kommende årene.

Viktig pressemelding fra Oncoinvent i dag. Fenomenale resultater så langt!

Robust safety profile demonstrated, no serious adverse events related to
Radspherin® reported
Presentation on October 4, 2023, at 11:55 a.m. CET (5:55 a.m. EDT)
Oslo 4, October 2023
Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid
cancers, today announced the presentation of preliminary 18-month safety and efficacy data from
its ongoing Phase 1/2A clinical trial evaluating the safety, tolerability, and signal of efficacy of
Radspherin® in patients with peritoneal carcinomatosis from colorectal cancer at the 13th
International Congress on Peritoneal Surface Malignancies of the Peritoneal Surface Oncology Group
International (PSOGI), to be held at the Palazzo del Cinema in Venice, Italy from October 4 - 6, 2023.
The presentation, titled “18-month safety and efficacy after intraperitoneal treatment with
224Radium-labelled microparticles (Radspherin) after cytoreductive surgery and hyperthermic
intraperitoneal chemotherapy (CRS-HIPEC) for colorectal peritoneal metastasis (PM)” will be
presented on October 4, 2023 from 11:55 a.m. to 12:05 p.m. CET (5:55 a.m. EDT).
“We are thrilled to continue to demonstrate the robust safety and efficacy profile of Radspherin®
with the presentation of 18-month data at PSOGI. At 18 months, none of the patients administered
Radspherin® at the recommended dose experienced peritoneal recurrences. Along with a
demonstrated robust safety profile, we believe Radspherin® has potential as a novel treatment,”
said Anders Månsson, Chief Executive Officer of Oncoinvent. “These data represent a significant
clinical milestone for Radspherin®, giving us confidence in its potential to prevent peritoneal
recurrence. We look forward to the continued clinical development of this promising therapy.”